Table 3

Immunohistochemical expression of arginase-1 and HepPar-1 according to the pattern of staining in all positive cases
Arginase-1 HepPar-1
Focal No (%) Diffuse No (%) Total positive Focal No (%) Diffuse No (%) Total positive
Hepatocellular carcinoma (HCC), (no=50): 10 (23.8) 32 (76.2) 42 15 (42.9) 20 (57.1) 35
well differentiated (no=11) 0 (0) 11 (100) 11 1 (9.1) 10 (90.9) 11
moderately differentiated (no=30) 8 (29.6) 19 (70.4) 27 10 (33.3) 12 (40) 22
poorly differentiated (no=9) 2 (50) 2 (50) 4 2 (22.2) 0 (0) 2
Metastatic carcinoma (MC) (no=38): 1 (100) 0 (0) 1 1 (16.7) 5 (83.3) 6
Colonic (no=25) (0) 0 (0) 0 1 (33.3) 2 (66.7) 3
Gastric (no=6) 0 (0) 0 (0) 0 0 (0) 3 (100) 3
Renal cell carcinoma (no=2) 0 (0) 0 (0) 0 0 (0) 0 (0) 0
Pancreas (no=2) 1 (100) 0 (0) 1 0 (0) 0 (0) 0
Lung (no=2) 0 (0) 0 (0) 0 0 (0) 0 (0) 0
Gall bladder (no=1) 0 (0) 0 (0) 0 0 (0) 0 (0) 0
Cholangiocarcinoma (no=12) 1 (100) 0 (0) 1 1 (50) 1 (50) 2
Non-neoplastic cirrhotic liver tissues adjacent to HCC(no=42) 0 (0) 42 (100) 42 0 (0) 42 (100) 42
Non-neoplastic liver tissue adjacent to MC (no= 9) 0 (0) 9 (100) 9 0 (0) 9 (100) 9
Normal liver tissues (no=10) 0 (0) 10 (100) 10 0 (0) 10 (100) 10

HepPar-1=hepatocyte paraffin antigen-1.

Radwan and Ahmed

Radwan and Ahmed Diagnostic Pathology 2012 7:149   doi:10.1186/1746-1596-7-149

Open Data